Transglutaminase 2: Development of therapeutic antibodies reveals four inhibitory epitopes and confirms extracellular function in fibrotic remodelling.

MLA

Maamra, Mabrouka, et al. “Transglutaminase 2: Development of Therapeutic Antibodies Reveals Four Inhibitory Epitopes and Confirms Extracellular Function in Fibrotic Remodelling.” British Journal of Pharmacology, vol. 179, no. 11, June 2022, pp. 2697–712. EBSCOhost, https://doi.org/10.1111/bph.15774.

APA

Maamra, M., Benayad, O. M., Matthews, D., Kettleborough, C., Atkinson, J., Cain, K., Bon, H., Brand, H., Parkinson, M., Watson, P. F., & Johnson, T. S. (2022). Transglutaminase 2: Development of therapeutic antibodies reveals four inhibitory epitopes and confirms extracellular function in fibrotic remodelling. British Journal of Pharmacology, 179(11), 2697–2712. https://doi.org/10.1111/bph.15774

Chicago

Maamra, Mabrouka, Osama Mehdi Benayad, David Matthews, Catherine Kettleborough, John Atkinson, Katharine Cain, Helene Bon, et al. 2022. “Transglutaminase 2: Development of Therapeutic Antibodies Reveals Four Inhibitory Epitopes and Confirms Extracellular Function in Fibrotic Remodelling.” British Journal of Pharmacology 179 (11): 2697–2712. doi:10.1111/bph.15774.